New hope for rare dementia: drug trial targets language loss
NCT ID NCT07154485
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests a new drug called NS101 in 15 people with a rare type of dementia that mainly affects language (semantic variant primary progressive aphasia). The goal is to see if the drug is safe and how it works in the body. Participants will receive either the drug or a placebo through an IV, and researchers will monitor side effects and measure drug levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA FRONTOTEMPORAL are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.